Strategies to inhibit tumour associated integrin receptors: rationale for dual and multi-antagonists by Sheldrake, Helen M. & Patterson, Laurence H.
 The University of Bradford Institutional 
Repository 
http://bradscholars.brad.ac.uk 
This work is made available online in accordance with publisher policies. Please refer to the 
repository record for this item and our Policy Document available from the repository home 
page for further information. 
To see the final version of this work please visit the publisher’s website. Access to the 
published online version may require a subscription. 
Link to publisher’s version: http://dx.doi.org/10.1021/jm5000547 
Citation: Sheldrake HM and Patterson LH (2014) Strategies to inhibit tumour associated integrin 
receptors: rationale for dual and multi-antagonists. Journal of Medicinal Chemistry. 57(15): 6301-
6315. 
Copyright statement: This document is the Accepted Manuscript version of a Published Work 
that appeared in final form in Journal of Medicinal Chemistry, copyright © 2014 American 
Chemical Society after peer review and technical editing by the publisher. To access the final 
edited and published work see http://dx.doi.org/10.1021/jm5000547 
Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-
antagonists 
Helen M. Sheldrake* and Laurence H. Patterson 
Institute of Cancer Therapeutics, University of Bradford, Bradford, UK. 
 
Abstract: The integrins are a family of 24 heterodimeric transmembrane cell surface 
receptors. Involvement in cell attachment to the extracellular matrix, motility, and 
proliferation identifies integrins as therapeutic targets in cancer and associated conditions; 
thrombosis, angiogenesis and osteoporosis. The most reported strategy for drug development 
is synthesis of an agent that is highly selective for a single integrin receptor. However, the 
ability of cancer cells to change their integrin repertoire in response to drug treatment renders 
this approach vulnerable to the development of resistance and paradoxical promotion of 
tumor growth. Here, we review progress towards development of antagonists targeting two or 
more members of the RGD-binding integrins, notably αvβ3, αvβ5, αvβ6, αvβ8, α5β1, and αIIbβ3, 
as anticancer therapeutics. 
 
Integrin structure and implications for drug development 
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Figure 1 Combinations of integrin subunits which form the 24 human receptors 
 
Recognition sequence Integrins  Major Ligands 
RGD αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, 
α5β1, α8β1,  αIIbβ3 
Vitronectin, Fibronectin, 
Osteopontin, Fibrinogen 
LDV and related sequences α4β1, α9β1, α4β7, αEβ7, αLβ2, 
αMβ2, αXβ2, αDβ2  
Fibronectin, Vascular Cell 
Adhesion Molecule 1, 
Mucosal Addressin Cell 
Adhesion Molecule-1, 
Intercellular Cell Adhesion 
Molecule-1 
GFOGER α1β1, α2β1, α10β1, α11β1 Collagen, Laminin 
Other α3β1, α6β1, α7β1, α6β4 Laminin 
Table 1 Integrin ligands and recognition sequences 
 
The integrin family comprises 24 transmembrane receptors, each a heterodimeric 
combination of 1 of 18 α and 1 of 8 β protein subunits. Their function is to integrate adhesion 
and interaction with the extracellular microenvironment with intracellular signalling and 
cytoskeletal rearrangement through transmitting signals across the cell membrane on ligand 
binding. They are usually classified into subfamilies based on the major protein recognised, 
type of cell expressing the receptor, or the presence of an I-domain in the α subunit (Figure 
1). The largest subfamily recognise the RGD tripeptide found in a range of extracellular 
matrix (ECM) ligands (Table 1), although these integrins also contain interaction sites for 
other proteins such as matrix metalloproteinases, and are able to bind other sequences. 
Integrins involved in immune functions recognise LDV and related sequences such as LDT 
and IDS. A subset of the collagen and laminin binding integrins recognise GFOGER, and the 
remaining laminin binding integrins recognise a range of peptide sequences with no common 
features currently reported.
1
  
The binding site for RGD and related sequences is located at the junction of the α and β 
subunits of RGD-binding integrins such as αvβ3 and α5β1. Key features of the RGD binding 
site are shown in Figure 2. Ligand binding has been explored through NMR studies, 
mutagenesis, X-ray structures of bound ligands and homology modelling.
2,3
 Ligand binding 
to the β subunit is primarily through an electrostatic interaction between a carboxylate group 
on the ligand and a positively charged metal ion (usually Mg
2+
) associated with the integrin 
subunit. The α subunit binds the basic arginine sidechain through interactions with several 
subunit specific acidic residues.  
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Figure 2 Key features of the RGD binding site 
 
Differences in binding site size and the identity of the arginine-binding residues have allowed 
development of integrin specific ligand mimetics which act as competitive antagonists; 
however, the information amassed in determining ligand specificity should also be applicable 
to the design of multi-integrin antagonists. NMR studies on peptides have shown that 
molecules binding to αIIbβ3 typically have a distance of 7.5-8.5 Å between the β carbons of 
arginine and aspartate, and compounds binding αvβ3 and α5β1 less than 6.7 Å.
4
 For 
peptidomimetic ligands, it is easier to measure the distance between acidic and basic groups 
acting as sidechain mimetics; typically 13.5-15.5 Å is required for anti-αIIbβ3 activity and 
10.0-13.8 Å for anti-αvβ3.
5,6
 α5β1 also binds molecules spanning ~13 Å, although its binding 
site is larger than αvβ3 with space for bulky residues adjacent to the RGD site and allowing 
more lipophilic interactions.
7
 α5β1 binding to the arginine sidechain has similarities to both 
αIIb and αv.
3
 αvβ5 is highly similar to αvβ3 in the ligand binding site region although homology 
modelling suggests the αvβ5 binding pocket is somewhat smaller and cannot accommodate 
large groups adjacent to the metal-ion dependent adhesion site.
8
 The structures of the other 
RGD-binding integrins, αvβ6, αvβ8, αvβ1 and α8β1, have not yet been studied in detail, although 
two recently reported homology models for αvβ6
9,10
 provide an important starting point to 
develop an understanding of antagonist selectivity. It has been shown experimentally that the 
common αv subunit and distinct β subunits allow the synthesis of small molecules with 
varying degrees of selectivity within the subfamily. α8β1 has not yet been proven to be a 
target for therapeutic intervention. It has some functions in common with other members of 
the subfamily, suggesting there may be some value in multi-targeting, but further 
investigations are required to establish whether this will be safe, effective, and possible. 
Integrins possess redundancy in ligand recognition, adhesion and signalling functions, and 
cells invariably express multiple integrins from several subfamilies. Crosstalk between 
integrins can affect cell functions, for example via trans-dominant inhibition where 
competition for intracellular signalling effectors means inhibition of the function of one 
integrin promotes activation, adhesion and signalling of another.
11
  
 
Despite the intense interest in integrins as targets in a range of diseases,
12,13
 the main strategy 
to date has been to develop a highly selective antagonist of a single integrin, whilst the 
deliberate development of dual antagonists has been little explored,
14
 with the exception of 
the application of α4β1/α4β7 antagonists in autoimmune disorders.
15
 The drive towards 
selectivity for a single integrin may reduce the effectiveness or safety of the developed 
antagonists, leaving them vulnerable to the development of resistance, or even paradoxical 
effects, as targeting one receptor promotes the upregulation of a related receptor binding the 
same ligand to maintain adhesion and signalling. 
This Perspective review summarises evidence of the importance, and interactions, of pairs 
and wider combinations of integrins in cancer progression and dissemination, and progress in 
the development of dual and multi-antagonists to efficiently target these processes. 
 
Dual antagonism 
αIIbβ3/αvβ3 
αIIbβ3 is normally expressed only on platelets and megakaryocytes. On platelet activation by 
any agonist, αIIbβ3 is activated and binds fibrinogen through its RGD and KQAGDV motifs 
causing platelet crosslinking thus thrombus formation.
16
 Antagonism of αIIbβ3 prevents 
platelet adhesion and aggregation, therefore it has been a popular target in the development of 
broad spectrum anti-thrombotic therapy.
17
 Three αIIbβ3 antagonists are currently approved for 
clinical use in the treatment of acute coronary syndrome and during percutaneous coronary 
intervention; the cyclic peptide Eptifibatide, small molecule Tirofiban and antibody 
Abciximab. Unlike the former two, Abciximab is not selective [IC50 (cell adhesion) αIIbβ3 6.5 
nM, αvβ3 9.8 nM, αMβ2 160 nM]
18
 and its ability to antagonise both β3 integrins and potentially 
reduce inflammation has been suggested as the reason for its better performance at preventing 
restenosis compared to αIIbβ3-specific  antagonists.
19,20
 
The most important sites of expression of αvβ3 are osteoclasts, where it controls attachment to 
the bone surface to form a sealing zone for bone resorption,
21
 and on active endothelial cells 
where it mediates vascular angiogenesis.
22
 The role of integrins in angiogenesis is complex; 
antagonism or knockout of αvβ3 can promote as well as inhibit angiogenesis, but a recent 
study has confirmed that αvβ3 is a valid target for preventing the early stages of 
angiogenesis.
23
  
αvβ3 is expressed on a wide range of tumors and associated vasculature, where it is associated 
with invasion, metastasis and poor prognosis.
24-27
 αvβ3 promotes site-specific metastasis to 
the lungs and bone; adhesion to fibronectin, vitronectin, osteopontin or bone sialoprotein 
allows the metastatic deposit to become established
28-32
 and tumoral αvβ3 signalling is 
required for bone deposition in osteoblastic lesions, in contrast with the recognised role of 
osteoclast αvβ3 in osteolytic metastases.
30,33-35
 
αIIbβ3 is abnormally expressed in melanoma and prostate tumors and is associated with 
increased tumor growth, recurrence and metastasis.
36-38
 Cells co-expressing αIIbβ3 and αvβ3 
show increased growth and angiogenesis in vivo, but reduced αvβ3 function due to its 
displacement or trans-dominant inhibition by αIIbβ3, suggesting that selectively targeted anti-
αvβ3 antagonists will prove clinically ineffective in dual β3 expressing tumors.
36,39
  
The full potential of dual αvβ3/αIIbβ3 integrin antagonism is evident when considering their 
roles in metastasis. β3 integrins promote lymphatic metastasis, and hematogenous metastasis 
through promoting extravasation from the primary tumor, cell adhesion, intravasation and 
tumor growth at the metastatic site. β3-mediated interactions between tumor cells and 
platelets promote platelet aggregation and release of growth factors, and increase cell survival 
through formation of a tumor-platelet microthrombus which protects circulating tumor cells 
from immune targeting and facilitates arrest and adhesion in blood vessels.
40-45
 
Both selective anti-αIIbβ3 antagonists, and αvβ3 antagonists have shown a wide range of 
anticancer effects (for a previous review see 
26
). Studies using Abciximab and related murine 
antibodies are particularly important in demonstrating the potential of dual β3 antagonism, 
although the problems of immunogenicity and bleeding associated with Abciximab suggest 
further development of small molecules is required to provide an attractive clinical candidate. 
Dual β3 antagonism with these antibodies was effective at blocking tumor growth and 
angiogenesis through targeting tumor cells’ interaction with platelets and endothelial cells, in 
addition to direct effects on tumor tissue.
46-48
 In a model of bone metastasis, daily treatment 
with m7E3 F(ab’)2 was effective at reducing growth of β3 negative tumors implanted in the 
tibia through acting on platelets and the bone microenvironment, indicating that this target 
will be applicable to a wide range of tumors.
47
 m7E3 F(ab’)2 pretreatment was also shown to 
reduce the development of lung metastases after intravenous injection of tumor cells as a 
model of the early stages of hematogenous dissemination.
49
 Combining two small molecule 
αIIbβ3 and αvβ3 antagonists has also been shown to be more effective than either agent alone at 
preventing tumor cell adhesion to endothelial cell or ECM.
50,51
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Figure 3 αIIbβ3/αvβ3 antagonists 
a.
The absence of standard deviation from a measurement 
indicates this data was not reported in the original reference. 
Dual antagonists have been obtained incidentally during the development of highly active 
selective αIIbβ3 or αvβ3 antagonists eg 1-4 (Figure 3).
52-54  
The cyclic peptides G4120 1 and G3580 (a related structure which unfortunately cannot be 
unambiguously identified)
55
 were found to be non-specific
56
 and have been used as tools in 
integrin biology and to demonstrate that inhibition of both αIIbβ3 and αvβ3 was effective at 
reducing restenosis, although there was no advantage in using G3580 [IC50 (cell free ELISA) 
αIIbβ3 1.5 nM; αvβ3 8 nM)] compared to a highly selective αIIbβ3 or αvβ3 antagonist alone.
57
 
SC56631 3, developed in an anti-αvβ3 antiosteoporotic programme, has been used as a tool 
compound to demonstrate that αvβ3 antagonism is cytotoxic to cysteine-rich protein 61 
overexpressing cancer cells which depend on integrin survival signalling; in this αIIbβ3 
negative in vitro model it was less effective when compared to antagonists with 
subnanomolar IC50s on αvβ3.
58
 SM265 6 has demonstrated anticancer effects in vitro and in 
vivo through binding to αvβ3 but possible contribution of αIIbβ3 to its in vivo efficacy has not 
been investigated.
59,60
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Figure 4 MN447 and related antagonists 
MN447 10 (Figure 4) is the only small molecule deliberately developed as a dual β3 
antagonist, intended as a small molecule analogue of Abciximab for the treatment of acute 
thrombotic events. Starting from a selective αIIbβ3 antagonist 7, altering substituents on the 
central aromatic ring gave compound 8 with nanomolar anti-αvβ3 and anti- αIIbβ3 activity in 
cell free ELISA but relatively ineffective at inhibiting αvβ3-mediated cell adhesion to 
vitronectin.
61
 Para-substitution about the central aromatic ring is required for αIIbβ3 activity; 
meta-substitution shortens the molecule thus yielding selective αvβ3 antagonists.
62
 Changing 
to a 4-aminopiperidine linker  9 improved the anti-adhesion activity,
61
 and adding either R = 
F, OH or OMe further increased potency and resulted in good water solubility.
63
 3-
aminopiperidine also afforded a highly active scaffold eg 11, 12.
64
 MN447 9 (R = OMe) was 
effective in treating thromboembolus-induced dysfunction of the heart muscle in vivo and is 
currently in preclinical development. Importantly, both MN447 10 and SC56631 3 have been 
demonstrated not to prolong bleeding time.
63,65
  
 
αvβ3/αvβ5  
αvβ5 has a similar expression pattern and function to αvβ3; both are highly expressed by 
activated endothelial cells and have similar roles in angiogenesis, promoting the angiogenic 
response to different growth factors.
66
 αvβ5 has been shown to be highly expressed on a wide 
range of tumor types in both cell lines and clinical material;
67
 this ubiquitous expression 
suggests it may be a good target receptor for developing tumor-directed therapies to benefit 
the widest range of patients. However, a number of tumors and associated vasculature co-
express αvβ3 and αvβ5;
68-70
 given that the two integrins engage the same ECM ligands and 
activate complementary cell signalling pathways
71-73
 to promote tumor progression, dual 
targeting will be necessary to effectively treat such tumors. 
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Figure 5 αvβ3/αvβ5 antagonists 
Screening of compounds which are highly active against αvβ3 reveals they frequently also 
possess similar activity against αvβ5 eg 13, 14 (Figure 5).
53
 Alternatively, dual antagonists 
have been deliberately prepared through screening to identify and optimise compounds with 
similar affinity for both integrins eg 15.
74
 14 is antiangiogenic and is highly effective at 
preventing adhesion of αvβ3/αvβ5 expressing melanoma cells to a range of RGD-containing 
ECM ligands, particularly osteopontin, indicating that it may be effective in reducing bone 
metastasis. It appears to be selective for inhibiting the active form of the integrin. Decreasing 
the length of the guanidine-bearing sidechain gave an αvβ5-selective agent.
75
  
SCH221153 16 was developed by screening a combinatorial RGD-mimetic library. The 
diaminopropionic acid aspartate mimetic was identified as essential for activity, and 
compounds optimised for high αvβ3 activity, resulting in the selective dual αvβ3/αvβ5 
antagonist 16.
76
 Despite a short half-life (12 minutes), 16 significantly reduced the growth of 
αv-negative melanoma xenografts, indicating that continuous exposure to high blood levels of 
integrin antagonist is not required to effectively inhibit angiogenesis, and contrasting with a 
subsequent report that drops in blood levels of an αvβ3 antagonist to subtherapeutic 
concentrations promote tumor growth.
77
  
S34961 17 was developed using the cycloheptene ring system to mimic the conformation of 
the RGD motif in natural integrin ligands. Other arginine sidechain mimetics such as 
tetrahydropyrimidine, tetrahydronaphthyridine, imidazoline and benzimidazoline also gave 
high dual antagonist activity.
78
 In vitro, 17 caused cell detachment and sensitized quiescent 
colon cancer cells to mitogen-activated protein kinase kinase inhibition by reducing integrin 
survival signaling.
79
 The resolved S isomer of 17 (S 36578-2) was shown to cause anoikis of 
endothelial cells.
80
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Figure 6 Cilengitide 
The cyclic pentapeptide Cilengitide 18 (Figure 6) is the first non-antibody integrin antagonist 
to progress to Phase III clinical trials for the treatment of cancer. The development of 
Cilengitide has been previously described by its inventors,
81
 so will be briefly summarised 
here. Briefly, Cilengitide was derived from the cRGDfV pentapeptide by N-methylation; 
methylation of valine was found to be the preferred position for increasing activity against 
αvβ3 whilst maintaining selectivity over αIIbβ3.
82,83
 Cilengitide is less selective against other 
RGD-binding integrins; it is usually described as an αvβ3/αvβ5 antagonist but has similar 
activity (12 nM) against both αvβ5 and α5β1. Addition of a second N-methyl group to the 
glycine, aspartic acid or D-phenylalanine residue improved the αvβ3 selectivity of the 
peptide.
84
 
The progress of Cilengitide through clinical trials was most recently summarised by Scaringi 
et al.
85
 It showed a good safety profile in all applications, and reached Phase III clinical trials 
against glioblastoma. Unfortunately, this first Phase III trial recently failed to reach its 
primary endpoint of increased progression-free survival, discouraging further development.
86
 
Preclinical and some clinical results indicate that Cilengitide should be used as a combination 
with radiotherapy or other chemotherapies.
87
 Notably, combination with cytotoxic 
chemotherapy in head and neck squamous cell carcinoma achieved 100% disease control in 
the Phase I cohort.
88
 Other preclinical studies indicate it may be effective in preventing or 
treating bone metastasis.
89,90
 
 
αvβ3/α5β1  
Tumors often overexpress α5β1 along with αvβ3 and other αv integrins.
91,92
 Both αvβ3 and α5β1 
allow interaction between cancer cells, endothelial cells and the ECM through common 
ligands, most notably fibronectin.
93
 αvβ3 has been shown to regulate the function of α5β1 and 
vice versa; selective inhibition of αvβ3 allows α5β1 mediated adhesion but not migration, 
whereas inhibition of both integrins more effectively prevented cancer cell adhesion.
94,95
 α5β1 
binding fibronectin promoted endothelial cells binding to vitronectin, and angiogenesis.
96
 
Inhibition of β1 integrins has been shown to promote tumor progression and metastasis by 
increasing the expression of β3 indicating that selective inhibition of α5β1 is likely to be 
ineffective as an anticancer therapy due to β3-mediated resistance. However, αvβ3 antagonism 
or combination β1/β3 antagonism is not vulnerable to this resistance.
97
 In contrast, αvβ3 
antagonism can increase tumor cell invasiveness in the presence of high levels of fibronectin 
due to increased α5β1 recycling; the effect of dual β1/β3 antagonism in these circumstances 
remains to be established.
98
 Such changes in receptor expression and usage in response to the 
chemical environment of a tumor may explain the contradictory results obtained in a minority 
of pathological studies, which show decreased expression of α5β1 as disease progresses. 
α5β1 has a similar proangiogenic function to αvβ3 and  knock-out of both α5 and αv is required 
to prevent vascular development since loss of one is generally compensated by the other.
99
 
Changes in the conformation of fibronectin favor binding by αvβ3 rather than α5β1 in the 
tumor microenvironment and promote vascular endothelial growth factor (VEGF) secretion; 
selective α5β1 inhibition stimulated VEGF secretion, but αvβ3 inhibition reduced it, suggesting 
that targeting α5β1 alone may have undesirable pro-angiogenic effects but targeting α5β1/αvβ3 
should not.
100
  
Selective α5β1 and αvβ3 antibodies had little effect on angiogenesis in the stromal 
microenvironment as single agents, but combination of selective antibodies completely 
blocked endothelial tube formation.
101
 Taken together, biological studies suggest that the 
safety and effectiveness of selective anti-α5β1 therapy requires further evaluation, whereas 
targeting α5β1 in combination with αvβ3 is likely to prove more efficient.  
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Figure 7 αvβ3/α5β1 antagonists 
Pyrrolidine derivatives eg 19 (Figure 7) with sulfonamides on the diaminopropanoate moiety 
proved to be dual αvβ3/α5β1 antagonists with moderate to good selectivity over αvβ5. 
Increasing the lipophilicity of the sidechains increased anti-integrin activity non-selectively, 
whereas switching from sulfonamide to carbamate gave α5β1 selective antagonists which was 
rationalized by the greater flexibility of the sulfonamide group allowing it to adopt 
conformations to fit both integrins’ binding pockets.102 
Dihydropyridinone antagonists were developed to provide more efficient antiangiogenic 
agents. These molecules lack the exosite binding motif seen in many RGD mimetic 
antagonists, and also contain very simple arginine mimetics. A primary amine was better than 
a guanidine group for activity on both receptors, and the most active compound 20 contained 
a simple butylamine chain.
103
 Dehydro β-amino acid 21 with a similar primary amines also 
showed dual antagonist activity.
104
 
Tetrapeptide mimetic 22 was also designed as an anti-angiogenic agent. A number of 
stereoisomers were effective in reducing the adhesion of cancer cells with similar levels of 
affinity for αvβ3, α5β1 and αvβ5, however only those containing S-aspartic acid inhibited 
human vascular endothelial cell tube formation in vitro.
105
   
Modifications of isoxazoline compounds to increase potency by introducing a spirocyclic 
linker gave selective or dual active αvβ3/α5β1 antagonists eg 23. Selectivity could be changed 
to favor α5β1 by introducing a carbamate group to the portion of the molecule interacting with 
the α-subunits.106 A related molecule 24 was used as a dual targeting agent to selectively 
deliver nanoparticles to tumors. Dual targeting was more effective at reducing angiogenesis 
than nanoparticles targeting αvβ3 alone which may be due to increased drug delivery when 
binding 2 receptors or to targeting a wider population of tumor and/or endothelial cells.
107
  
 
αvβ6/αvβ3 and αvβ6/α5β1 
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Figure 8 Dual αvβ6 antagonists 
αvβ6 is upregulated during inflammation and cancer progression, particularly in colon, head 
and neck and pancreatic cancers.
108
 It shares with αvβ3 the ability to localize and activate 
matrix metalloproteinases (MMPs) and activate transforming growth factor-β1 (TGF-β1). 
There are few examples of small molecules targeting αvβ6; the first selective antagonist was 
developed alongside dual and tri-integrin antagonists 25 and 26 (Figure 8). Sterically 
demanding aromatic sidechains on the aspartate sidechain mimetic reduce affinity for αvβ5 
while increasing it for αvβ6.
109
 The cell-based adhesion assays used in this study provide a 
useful illustration of experimental design to selectively measure inhibition of a single integrin 
using a cell line expressing several RGD-binding integrins. 
A cyclic peptide 27 with high affinity for αvβ6 and α5β1 yet completely inactive against αvβ3, 
αIIbβ3 and αvβ5 has recently been developed.
9
 Docking with a homology model of αvβ6 
suggested that the high affinity for αvβ6 and selectivity over αvβ3 is due to D-phenylglycine 
occupying a hydrophobic binding pocket in the β6 subunit which is larger than the 
corresponding pocket in β3 thus directing the lysine sidechain to forms a salt bridge to the β6 
subunit 
 
Multi-integrin antagonism 
The majority of cell types express a range of integrins from several subfamilies on their 
surfaces. It is extremely unlikely that a single antagonist could affect the entire family of 
integrin receptors due to significant differences in structures of both α and β subunits. The 
most obvious difference is the presence or absence of an I-domain in the α subunit controlling 
the site and mode of ligand binding, but differences in structure of the cytoplasmic domains 
such as the long tail present in β4 also modulate integrin function and the binding of cell-
penetrating molecules. Despite the differences in structure, it is possible to develop an 
antagonist with similar affinities for most or all members of a particular subfamily. 
Recent development of rabbit monoclonal antibodies suitable for use in formalin-fixed 
paraffin-embedded tissue samples has paved the way for extensive studies of the expression 
of the αv integrin subfamily in primary tumors and metastases, with a particular focus on 
brain tumors.
67
  αvβ3, αvβ5 and αvβ8 are frequently coexpressed on gliomas, and increased 
gene expression is associated with decreased survival; αvβ5 and αvβ8 were more common in 
glioblastomas compared to less aggressive tumor types.
110
 Evaluation of integrin expression 
in primary tumors and metastases to the brain revealed αv integrins were invariably present 
on tumors and upregulated in brain metastases with the specific heterodimers involved 
depending on the tumor type; αvβ5 is present in most primary tumors, αvβ3 and αvβ8 are 
upregulated in metastases compared to primary tumors. The relative levels of αvβ6 in primary 
tumor and metastasis vary between studies.
111,112
  
Based on these results, several suggestions have been made regarding appropriate 
combination of integrins to target; αvβ3/αvβ5 antagonists will target blood vessels but not 
tumor cells and metastases which often express αvβ6 and αvβ8 as well as αvβ3. αvβ6/αvβ8 
antagonists may control primary tumor growth and metastasis without normal tissue toxicity, 
but αvβ8 has not been as extensively studied as the other integrins thus its role in 
tumorigenesis requires further investigation. Overall, the range of integrins expressed on 
tumors suggests pan-αv antagonism will be required for efficient prevention and treatment of 
metastases to the brain since it is the only approach that can target both tumors and the 
supporting stroma and endothelial cells.
111,112
  
Pan-αv antagonism should be broadly applicable in the treatment of metastasis. αv signalling 
has been shown to be highly significant in prostate tumor progression and dissemination. 
Knockdown of αv inhibited the growth of αvβ1/αvβ5 expressing prostate cancer xenografts in 
bone through interfering with tumor-microenvironment interactions,
113
 and reduced 
orthotopic tumor growth and bone metastasis initiated by intracardiac injection of prostate 
cancer stem cells.
114
 Antibodies and small molecules targeting αv have demonstrated 
antimetastatic effects in a number of tumor types and are reviewed below. 
The expression of αvβ1 on tumors and metastases has not yet been investigated, and the 
studies described above do not consider the contribution of non-αv RGD-binding integrins to 
tumor progression and metastasis. α5β1 and αIIbβ3 respectively support angiogenesis and 
hematogenous metastasis, and can both promote tumor growth, thus should also be 
considered when designing multi-targeted antagonists. 
 
Anti-αv antibodies 
Antibodies binding all αv integrins have progressed to clinical trials. Intetumumab 
(CNTO95), an anti-αvβ1/αvβ3/αvβ5/αvβ6 antibody developed to target a wide range of cancer 
types, was effective at reducing or preventing tumor growth in preclinical models through 
both tumor specific effects on αvβ3/αvβ5, and more clinically relevant action on integrins on 
both the tumor and surrounding cells.
115
 It also diminished hematogenous metastasis to the 
brain and lungs by reducing the ability of cells to migrate and invade from the vasculature to 
the metastatic site.
116,117
 The anti-metastatic effect was independent of treatment timing, but 
treatment at the time of removing the primary tumor has been suggested to prevent the 
formation of metastases from tumor cells released by surgery.
116
 Importantly for the 
development of further pan-αv targeted drugs, intetumumab has been shown to be safe in both 
preclinical and clinical studies, despite binding to αv integrins in a wide range of normal 
tissues.
118
   
In Phase I trials of intetumumab, partial responses occurred in patients with a number of 
cancer types including metastatic melanoma, angiosarcoma and ovarian cancer,
119,120
 and a 
larger trial on melanoma showed anecdotal evidence of improved overall survival.
121
 Despite 
encouraging results in a Phase I trial on metastatic prostate cancer, in Phase II, intetumumab 
did not improve progression free survival, but did reduce expression of biomarkers of bone 
turnover.
122,123
 Although these results seem to refute the assertion that multi-integrin 
inhibition will be effective clinically they must be treated with caution since both low 
exposure to intetumumab resulting from unfavorable pharmacokinetics and varying levels of 
target expression in the patients enrolled have been noted during trials.
121
 Use of a small 
molecule with better penetration and half-life in the body may provide more reliable 
evidence. 
In preclinical studies, the humanised deimmunised anti-αv antibody DI17E6 prevented the 
growth of melanoma xenografts in mice through acting on human αvβ3 expressed on 
tumors.
124
 DI17E6 was well-tolerated in Phase I trials in healthy subjects, and those with 
progressing prostate cancer bone metastasis. Clinical trials in prostate cancer are ongoing 
after multiple patients on the Phase I trial showed stable disease or partial response.
125,126
  
 
Disintegrins 
Snake venom disintegrins are a family of small proteins (typically 45–84 amino acids in 
length) that inhibit multiple integrins including the αv subfamily, αIIbβ3, α5β1 and others in the 
β1 family. As a result of these wide and variable anti-integrin profiles, disintegrins have 
become useful as probe molecules (eg echistatin), and starting points for anticancer and 
antithrombotic drug development; the clinically used anti-αIIbβ3 cyclopeptide Eptifibatide was 
developed based on the KGD sequence of the αIIbβ3 specific disintegrin barbourin.
127,128
  
Some recent studies investigating the anticancer effects of disintegrins and other snake 
venom sourced molecules which bind multiple integrins are summarised in Table 2. The 
majority of these examples contain the RGD recognition sequence, however this is not a 
requirement for disintegrin activity. Other related sequences also confer high activity on the 
RGD-binding subfamily,
129
 or promote binding to α4 and β1 integrins. Not all disintegrins 
have been fully characterised for their integrin binding profile; many other examples
130-132
 
show interesting anti-platelet and anti-tumor effects.  
Binding a wider range of integrins than many currently used selective antibodies and small 
molecules is likely to make disintegrins more efficient in controlling cancer growth and 
dissemination since they will be able to block multiple redundant adhesion mechanisms and 
signalling pathways. For example, acurhagin C inhibits growth of melanoma cell lines which 
are unaffected by the αvβ3/αvβ5 antagonist cRGDfV.
133
 Many disintegrins inhibit platelet 
aggregation, and thus tumor-platelet interactions involving αIIbβ3. They are notably effective 
at preventing the formation of lung metastases when coinjected intravenously with cancer 
cells.
131,134,135
 Vicrostatin, an echistatin/contortrostatin chimera, is selective for activated 
platelets and caused no bleeding side effects in vivo, suggesting anti-αIIbβ3 activity can be 
safely incorporated into an effective anti-metastatic agent.
136
 
The clinical use of disintegrins presents some challenges. Naturally produced supply is 
limited, expensive and hazardous to collect, whereas recombinant disintegrins may have 
different properties to the naturally sourced material. The echistatin/contortrostatin chimera 
vicrostatin can be reliably produced recombinantly, avoiding difficulties in supplying 
contortrostatin in large quantities,
136
 and contortrostatin itself has been produced 
recombinantly
137
 and formulated as liposomes to improve half-life and facilitate intravenous 
administration.
138
  
Preclinical experiments with disintegrins indicate that multi-antagonists of the RGD-binding 
integrins are effective, and generally safe, anticancer agents. Knowledge of disintegrin 
structures, specifically the conformation of the loop containing the recognition motif, and the 
nature of the amino acids flanking the RGD tripeptide will provide inspiration for small 
molecule development.  
Disintegrin Integrins bound Recognition 
sequence 
Anticancer effects Ref 
Salmosin αIIbβ3, αv 
subfamily, β1 
subfamily 
RGD Reduces hematogenous 
metastasis. Blocks cell survival 
signalling. 
134,139
 
Contortrostatin αIIbβ3, αvβ3, αvβ5, 
α5β1 
RGD Anti-angiogenic. Reduces 
xenograft growth in bone. 
Reduces hematogenous 
metastasis. 
Synergistic with docetaxel 
135,140
 
Vicrostatin  αIIbβ3, αvβ3, αvβ5, 
α5β1 
RGD Anti-angiogenic: disrupts 
endothelial cell cytoskeleton. 
136
 
Reduces tumor growth 
Acurhagin-C αv-subfamily 
(excluding αvβ5), 
α5β1 
ECD Inhibits melanoma cell 
proliferation and migration. 
Synergistic with methotrexate 
133
 
 
PIVL αvβ3, αvβ5, αvβ6, 
α1β1, α5β1 
Not 
determined 
Inhibits glioblastoma cell 
invasion and migration 
141
 
Eristostatin αIIbβ3, α4β1, αv 
subfamily 
RGD Reduces hematogenous 
metastasis. 
Affects natural killer cell 
function and interaction with 
melanoma cells. 
142
 
 
Viridistatin αIIbβ3, αvβ3, 
other αv 
subfamily 
RGD Inhibits tumor cell invasion and 
migration. 
Reduces hematogenous 
metastasis. 
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Table 2 Recent examples of disintegrins with anti-cancer activity 
N N
N
NN
H H
N
CO2H
HN
S
O
O
OMe
GLPG0187 33
H
N
OH
H
N
N
HO
N
H
O
H
N
O
CO2H
Br
CWHM12 34
X
H
N
H
N
N
HO
N
H
O
H
N
O
CO2H
Cl Br
X = COH, S137 29
X = N, S247 30
OH
N
H
NH
H2N
S
H
N
O
CO2H
HN
S
O
O
R
R
R
R = Me, BCH-15046 31
R = H, BCH-14661 32
N
H
N
N O
N
CO2H
O
O
28
 
Figure 9 Multi-integrin antagonists 
 αvβ1 αvβ3 αvβ5 αvβ6 αvβ8 α5β1 α2β1 α4β7 α10β1 αIIbβ3 Ref 
28 2.6
a
 0.65
a
 1.7
a
 2660
a
 NT NT NT NT NT 27
b
 
143
 
S137 29 
10.4 
± 
7.3
b
 
1.6 ± 
1
b
 
18.1 
± 
14.6
b
 
11.7 
± 
10.7
b
 
1.71 
± 
0.05
b
 
316 ± 
228
b
 
NT NT NT 
257 ± 
29
b
 
144
 
S247 30 
1.59 
± 
0.41
b
 
0.40 ± 
0.24
b
 
1.50 
± 
1.26
b
 
1.13 
± 
0.55
b
 
0.65 
± 
0.21
b
 
64 ± 5
b
 NT NT NT 
380 ± 
92
b
 
144
 
BCH-
15046 31 
NT 
3.5 ± 
0.9
a
 
60 ± 
50
a
 
NT NT 20 ± 4
a
 NT NT NT 0.2
b
 
145
 
BCH-
14661 32 
NT 
0.033 
± 
0.016
a
 
72 ± 
37
a
 
NT NT 
640 ± 
256
a
 
NT NT NT 0.3
b
 
145
 
SC56631 3 317
a
 
10
b
 
120
a
 
23
a
 NT NT ~70000
a
 NT NT NT 9
b
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GLPG0187 
33 
1.3 ± 
0.1
b
 
3.7 ± 
0.6
b
 
2.0 ± 
0.6
b
 
1.4 ± 
0.3
b
 
1.2 ± 
0.3
b
 
7.7 ± 
4.0
b
 
>10
4,b
 >10
4,b
 NT >10
5,b
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CWHM12 
34 
1.8 ± 
0.9
b
 
0.8 ± 
0.6
a
 
61 ± 
17
a
 
1.5 ± 
2.5
a
 
0.2 ± 
0.1
b
 
NR
a
 >5000
b
 NT >5000
b
 >5000
b
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Table 3. IC50 (nM) of multi-RGD antagonists in cell-based (
a
) and cell-free (
b
) ELISA. NT = 
not tested. NR = tested but not reported.  
A smaller number of small molecule multi-RGD antagonists have been reported compared 
with αvβ3 or αvβ3/αvβ5 targeted agents, although complete testing for selectivity may reveal 
more; for example screening ‘selective’ αvβ3 antagonists eg. 28 and SC56631 3 revealed 
activity on αvβ1 as well as αvβ5. In this regard the orally bioavailable S137 29 was described 
initially as an αvβ3 antagonist, but proved to be a pan-αv antagonist with highest activity 
against αvβ3/αvβ8. Switching to a pyridine ring system gave S247 30 which has increased 
affinity for all αv integrins and measurable activity against α5β1.
144
 S247 30 decreased liver 
metastasis from established colon cancer splenic xenografts, and continuous infusion reduced 
lung metastasis from orthotopic implantation of an aggressive breast cancer cell line although 
it did not reduce growth of the primary tumor in either case.
144,148
 In some studies, S247 30 
appeared to exert most effect on the early stages of metastasis,
149
 however S137 29 reduced 
metastatic tumor burden when administered orally after the primary tumor was removed.
144
 
Since this mimics the situation of patients with advanced cancer following surgery, it 
suggests anti-αv agents will be useful as adjuvant or palliative therapy. 
The anti-angiogenic BCH-15046 31 was shown to be more effective in a range of in vitro 
angiogenesis models than the related αvβ3 selective compound BCH-14461 32 as a result of 
its ability to prevent both MMP-dependent and collagen-dependent cell proliferation and 
survival which require α5β1.
145
 The high activity of both 31 and 32 against αIIbβ3 suggests they 
would show further improved antitumor effects in vivo. GLPG0187 is a nanomolar antagonist 
of 6 integrins developed as a treatment for bone metastasis in breast and prostate 
cancers;
146,150
 its structure has not been reported, but patent analysis suggests 33. In 
preclinical studies, GLPG0187 has been shown to be a potent anti-angiogenic and anti-
osteoporotic agent, effective in reducing both new and established bone metastases.
151,152
 It 
was shown to be safe and effective at reducing biomarkers of bone turnover in a Phase I trial 
in healthy volunteers, and has now progressed into trials in patients with advanced cancers. 
An isopropyl malonate prodrug to increase oral bioavailability is also being investigated.
153
 
CWHM12 34 is a nanomolar antagonist of all αv integrins structurally related to S137 29. 
CWHM12 34 has not been investigated in cancer, but was effective in preventing and treating 
renal and pulmonary fibrosis.
147
 Cilengitide was not effective here, suggesting that blockade 
of αvβ3 and αvβ5 alone is not sufficient to have therapeutic effect in fibrosis perhaps because it 
leaves other αv integrins able to activate TGF-β1. The effects of subtle differences in integrin 
affinity between GLPG0187 and CWHM12 34, most notably on αvβ5 and α5β1, remain to be 
investigated. 
Discussion 
Despite the large number of integrin antagonists reported in the medicinal chemistry 
literature, a very small number of agents have progressed successfully into the clinic. 
Multiple hypotheses have been proposed to explain the lack of efficacy seen in clinical trials 
of agents such as Cilengitide, ranging from reversibly binding antagonists promoting changes 
in integrin receptor conformation and signalling at low concentrations to issues of selectivity 
between cell types. In particular, lack of selectivity between the members of an integrin 
subfamily has been suggested as a safety issue complicating clinical applications of targeted 
therapy; to overcome this, the use of highly selective small molecules to provide a tightly 
aimed targeting of a single integrin expressed by a particular cancer has been proposed.
86
 
The use of small molecules targeted to specific integrins as carriers may be useful in 
delivering cytotoxic agents to cancer cells. However, it does not directly target the integrin 
mediated processes which are key to tumor proliferation and dissemination, will require the 
development of a large number of individual targeting agents, and is still liable to failure as 
cancer cells alter their integrin expression in response to changes in the surroundings or to 
drug treatment. In contrast, a single small molecule multi-integrin antagonist will provide an 
anticancer agent applicable to a wide range of tumors which is not vulnerable to the 
development of resistance or paradoxical effects by changes in expression of particular 
members of an integrin subfamily. Studies using disintegrins and anti-αv antibodies have 
shown that multi-integrin antagonism is likely to be both safe and effective; the ability to 
bind integrins on multiple cell types does not cause unacceptable normal tissue toxicities, and 
should result in improved anticancer effects through inhibiting a wide range of tumor and 
stromal cell interactions with the microenvironment. Further work is required to determine 
the optimum combination(s) of integrins that should be targeted by an efficient multi-
antagonist. A number of the RGD-binding subfamily, αvβ3, αvβ5 and αvβ6, are already well-
established anticancer targets. The biological functions of others, such as αvβ8 and α8β1, still 
largely remain to be defined. Both αv and β1 are widely expressed in cells, and the αvβ1 
heterodimer may become more important as other related receptors are inhibited. Antagonism 
of αIIbβ3 is frequently a cause for concern due to its involvement in platelet aggregation and 
hence the possibility of vascular bleeding as a serious side effect. Early selective αIIbβ3 
antagonists did have a poor safety profile; however, it is noteworthy that the few small 
molecule dual αIIbβ3/αvβ3 antagonists investigated to date do not cause prolongation of 
bleeding time or related side effects. That accepted, the potential benefit of αIIbβ3/αvβ3 
antagonism on preventing life-threatening tumor associated thrombus embolism should not 
be underestimated. Given the great potential of such compounds in combating tumor 
dissemination, it is important that development continues and αIIbβ3 is considered for 
inclusion as part of the target profile for multi-integrin antagonists.  
The medicinal chemistry literature contains a vast number of integrin antagonists. Most of 
these are selective and designed as antagonists of a single receptor. However, their selectivity 
has usually been determined against only 2 or 3 related integrins. Full screening of 
compounds against an entire subfamily is required to determine whether an antagonist is 
genuinely selective or an unrecognised dual or multi-antagonist. This knowledge will 
improve the interpretation of biological results obtained using integrin antagonists as probe 
molecules, and provide structure-activity data to assist with the design of further antagonists 
with defined selectivity. Combined with full analysis of the integrin expression profile in 
different diseases, and how it changes in response to drug treatments, such investigations will 
provide lead molecules not just for cancer, but also other diseases involving angiogenesis, 
atherosclerosis, fibrosis, and viral infections. 
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